HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDM/SCT) IN LIGHT-CHAIN DEPOSITION DISEASE (LCDD) AND IMMUNOGLOBULIN DEPOSITION DISEASE (IGDD).
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Filgrastim (Primary) ; Melphalan (Primary)
- Indications Lymphoproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Feb 2012 Planned end date changed from 1 Oct 2014 to 1 Feb 2030 as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned End Date changed from 1 Oct 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.